Clinical Applications, Patents, and Challenges in Cancer Immunotherapy

Tumor immunology has undergone a transformative era propelled by the advent of immunotherapy, reshaping the landscape of cancer treatment. Two prominent forms, adoptive cell transfer (ACT) and immune checkpoint inhibitors (ICIs), have yielded enduring therapeutic outcomes. However, their effectiveness varies across cancer subsets, limiting their applicability. The tumor microenvironment’s (TME) immune infiltrates play a pivotal role in shaping tumor development and influencing clinical prognoses. Profiling tumor-infiltrating cells can unveil the intricacies of cancer-immune evasion, paving the way for innovative therapeutic strategies. Yet, the TME’s intricate and dynamic nature poses challenges in accurately delineating intratumoral immune cells. Recent advancements, notably single-cell RNA technology, aim to refine this analysis. Effective immune responses can eliminate or alter cancerous cells. However, cancer cells deploy various mechanisms, such as flaws in antigen presentation, upregulation of negative regulatory pathways, and recruitment of immunosuppressive cell populations, thwarting immune surveillance and hindering effector functions. Immunotherapy’s impact on oncology is revolutionary, fortifying the body’s defenses against cancer cells. While the use of the host immune system against cancer dates back over a century, recent studies have made significant strides. Despite varying response rates and unclear mechanisms, immunotherapy consistently demonstrates enduring clinical responses in diverse cancer types. Understanding TME immune infiltrates is paramount for enhancing response rates and devising novel immunotherapy-based cancer treatments. The chapter explores the evolution of cancer immunotherapy, recent insights into immune cell infiltration in cancer, their implications for immunotherapy, and potential clinical applications, providing a comprehensive overview of this groundbreaking field.